Literature DB >> 19469889

Reduced numbers of circulating gammadelta T cells in patients with bullous pemphigoid.

Eva Oswald, Paul Fisch, Thilo Jakob, Leena Bruckner-Tuderman, Stefan F Martin, Anne Rensing-Ehl.   

Abstract

Bullous pemphigoid (BP) is an autoimmune blistering skin disease characterized by autoantibodies to hemidesmosomal proteins. The initiation and regulation of the autoimmune response are poorly understood. We analysed cell subsets with immunoregulatory functions in untreated BP patients. While the numbers of circulating NKT and NK cells were normal, gammadelta T cells were reduced in BP patients. gammadelta T cells were rarely detected in lesional skin, arguing against their sequestration in the skin. In most patients, clinical remission and reduction of autoantibody titres after immunosuppressive therapy was not accompanied by an increase of circulating gammadelta T cells. V gammadelta gene usage was not altered in BP patients and the gammadelta T cells of BP patients were functional as they proliferated in response to isopentenyl pyrophosphate. Our data provide a basis for further investigations on the role of gammadelta T cells in the immunopathogenesis of BP.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19469889     DOI: 10.1111/j.1600-0625.2009.00875.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  3 in total

Review 1.  Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications.

Authors:  Ilan Bank; Victoria Marcu-Malina
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Defining the nature of human γδ T cells: a biographical sketch of the highly empathetic.

Authors:  Shirin Kalyan; Dieter Kabelitz
Journal:  Cell Mol Immunol       Date:  2012-10-22       Impact factor: 11.530

Review 3.  Resolution in bullous pemphigoid.

Authors:  Christian D Sadik; Enno Schmidt
Journal:  Semin Immunopathol       Date:  2019-11-15       Impact factor: 9.623

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.